Equity Profile

CRMD

CorMedix Inc.

Health CarePharmaceuticals$662.1M

May14Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:30 AM EDT

CorMedix Inc. Beats on EPS, Stock Down 0.12%

Metric	Actual	Expected	Surprise
EPS	$0.43	$0.33	+24.64%
Revenue	—	$105M	—

management commentary, guidance changes, and full analysis available with Pro.

CorMedix Inc. Beats on EPS, Stock Down 0.12%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.43	$0.33	+24.64%
Revenue	—	$105M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

CorMedix Inc. reported better-than-expected earnings per share, which is a positive sign for the company. However, the stock saw a slight decline of 0.12%, indicating that investors may have been looking for more clarity on revenue performance or future guidance. The lack of revenue results and management commentary could have contributed to the muted stock reaction.

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with unmet medical needs....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$0.33

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$105M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with unmet medical needs. Operating in the health care sector, its work is particularly relevant as the demand for effective treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+37.26%

Avg Stock Reaction

-1.74%

Last Quarter Recap

In Q4-2025, CorMedix reported an EPS of $0.16, significantly missing the estimate of $0.86, leading to a notable stock decline. This follows a strong performance in Q3-2025 where they exceeded expectations with an EPS of $1.26.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect CorMedix to report an EPS of $0.33 and revenue of $105M for Q1-2026, reflecting cautious optimism after a mixed performance in previous quarters.

Bull Case

If CorMedix meets or exceeds the EPS and revenue expectations, it could signal a strong recovery and renewed investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet these expectations, particularly after a significant miss last quarter, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$0.33

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$105M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS meet the consensus estimate of $0.33?

This figure is crucial for assessing the company's profitability and could significantly influence investor sentiment.

What revenue figures will CorMedix report, and how do they compare to the $105M consensus?

Revenue performance will provide insights into market demand and the effectiveness of the company's sales strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly cautious given the recent EPS miss, but the strong performance in Q3-2025 suggests a potential for recovery that isn't fully reflected in current estimates.

Supporting Evidence

The options market is pricing a 14.31% move, which is lower than the historical average of 17.05%, indicating potential underestimation of volatility.

CorMedix has a strong EPS beat rate of 88%, suggesting a higher likelihood of exceeding expectations.

Key Risk

If the company reports an EPS significantly above $0.33, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching these earnings due to the mixed results from previous quarters, making this report pivotal for future investor confidence.

Bull Confirmed If

Achieving an EPS of $0.33 or better would confirm the bull case and signal a strong recovery.

Bear Confirmed If

An EPS below $0.33 would reinforce concerns about the company's profitability and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±14.31%

Historical Avg

±17.1%

Pricing cheap

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±14.3% while CRMD has averaged ±17.1% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.8%

30d HV

36.4%

Calls (63K)P/C Ratio: 0.20Puts (17K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CorMedix beats expectations, history suggests a modest positive reaction, potentially confirming a turnaround in performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a significant decline, as history indicates an average drop of around -11.52% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on sales growth and market demand for CorMedix's products.
2Updates on any new product developments or regulatory approvals.
3Management's outlook on future earnings and revenue guidance.
4Insights into cost management and operational efficiency improvements.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Cronos Group Inc.

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with unmet medical needs....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$0.33

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$105M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+37.26%

Avg Stock Reaction

-1.74%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect CorMedix to report an EPS of $0.33 and revenue of $105M for Q1-2026, reflecting cautious optimism after a mixed performance in previous quarters.

Bull Case

If CorMedix meets or exceeds the EPS and revenue expectations, it could signal a strong recovery and renewed investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet these expectations, particularly after a significant miss last quarter, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$0.33

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$105M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS meet the consensus estimate of $0.33?

This figure is crucial for assessing the company's profitability and could significantly influence investor sentiment.

What revenue figures will CorMedix report, and how do they compare to the $105M consensus?

Revenue performance will provide insights into market demand and the effectiveness of the company's sales strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly cautious given the recent EPS miss, but the strong performance in Q3-2025 suggests a potential for recovery that isn't fully reflected in current estimates.

Supporting Evidence

The options market is pricing a 14.31% move, which is lower than the historical average of 17.05%, indicating potential underestimation of volatility.

CorMedix has a strong EPS beat rate of 88%, suggesting a higher likelihood of exceeding expectations.

Key Risk

If the company reports an EPS significantly above $0.33, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching these earnings due to the mixed results from previous quarters, making this report pivotal for future investor confidence.

Bull Confirmed If

Achieving an EPS of $0.33 or better would confirm the bull case and signal a strong recovery.

Bear Confirmed If

An EPS below $0.33 would reinforce concerns about the company's profitability and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±14.31%

Historical Avg

±17.1%

Pricing cheap

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±14.3% while CRMD has averaged ±17.1% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.8%

30d HV

36.4%

Calls (63K)P/C Ratio: 0.20Puts (17K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CorMedix beats expectations, history suggests a modest positive reaction, potentially confirming a turnaround in performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a significant decline, as history indicates an average drop of around -11.52% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on sales growth and market demand for CorMedix's products.
2Updates on any new product developments or regulatory approvals.
3Management's outlook on future earnings and revenue guidance.
4Insights into cost management and operational efficiency improvements.